Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2025 | Updated results of axitinib and nivolumab in previously treated mRCC

Elizabeth Plimack • 15 Feb 2025
GU Cancers 2025
Genitourinary Cancer Kidney Cancer Antibodies Axitinib Checkpoint Inhibitors Nivolumab

Elizabeth Plimack, MD, MS, Fox Chase Cancer Centre, Philadelphia, PA, gives an overview of results from a Phase I/II study (NCT03172754) of axitinib with nivolumab in patients with pre-treated metastatic renal cell carcinoma (mRCC). The combination achieved a notable disease control rate and encouraging overall survival, with some patients remaining progression-free after stopping therapy at two years. Adverse events were consistent with known profiles. This interview took place at the ASCO GU Cancers Symposium 2025 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Elizabeth Plimack

RETAIN-2: risk enabled therapy after neoadjuvant chemo-IO in MIBC
1:33
RETAIN-2: risk enabled therapy after neoadjuvant chemo-IO in MIBC
Elizabeth Plimack • 15 Feb 2025
CheckMate 274: additional survival outcomes of adjuvant nivolumab in MIBC
1:02
CheckMate 274: additional survival outcomes of adjuvant nivolumab in MIBC
Elizabeth Plimack • 15 Feb 2025
NIAGARA: impact of pCR on outcomes of durvalumab with NAC in MIBC
0:35
NIAGARA: impact of pCR on outcomes of durvalumab with NAC in MIBC
Elizabeth Plimack • 15 Feb 2025
DAD trial: combining sacituzumab govitecan and EV for the treatment of bladder cancer
0:52
DAD trial: combining sacituzumab govitecan and EV for the treatment of bladder cancer
Elizabeth Plimack • 22 Oct 2023

Related Videos

Current and emerging systemic strategies in biochemically relapsed prostate cancer
2:45
Current and emerging systemic strategies in biochemically relapsed prostate cancer
Ashwin Sachdeva • 16 May 2026
How has SABR improved radiotherapy practice in kidney cancer?
1:06
How has SABR improved radiotherapy practice in kidney cancer?
Shankar Siva • 16 May 2026
Which patients with kidney cancer may benefit from SABR treatment?
1:58
Which patients with kidney cancer may benefit from SABR treatment?
Shankar Siva • 16 May 2026
Management of brain metastasis in patients with poor-risk testicular cancer
1:03
Management of brain metastasis in patients with poor-risk testicular cancer
Darren Feldman • 30 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals